miR ‐330‐3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4
APMIS · 2026-07 · 134 (7)
DOI: 10.1111/apm.70237 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, online erschienen am 20.07.2026. Verfasst von Yuanyuan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Base Training, Shanghai Fengxian District Central Hospital, Shanghai, China. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Myeloid, Acute. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
MicroRNAs (miRNAs) serve as crucial regulators in the development of various cancers. Studies have mentioned that miR‐330‐3p is reduced in Acute myeloid leukemia (AML). Our research objectives included determining the regulatory roles and underlying mechanisms of miR‐330‐3p in AML progression. miR‐330‐3p expression in AML was quantified through qRT‐PCR. The clinical relevance of miR‐330‐3p in AML progression, diagnosis, and prognosis was assessed by chi‐square, ROC, Cox, and Kaplan–Meier survival analysis. The impacts of miR‐330‐3p on AML cell function were examined by CCK8 and Transwell assay. The targeting relationship between miR‐330‐3p and SYTL4 was analyzed via database and luciferase assay. miR‐330‐3p was obviously reduced in AML. Low miR‐330‐3p expression was related to adverse clinical features of AML, suggesting AML progression. miR‐330‐3p performed well in differentiating AML patients from healthy individuals, and reduced miR‐330‐3p expression was significantly related to poorer survival outcomes in patients with AML. miR‐330‐3p upregulation potently inhibited AML cell proliferation, migration, and invasion. Furthermore, SYTL4 was a target gene of miR‐330‐3p. And rescue tests demonstrated that miR‐330‐3p and SYTL4 jointly participate in the development of AML. In conclusion, miR‐330‐3p inhibited the development of AML by targeting SYTL4; miR‐330‐3p may serve as a valuable prognosis and diagnostic biomarker for AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Base Training, Shanghai Fengxian District Central Hospital, Shanghai, China.
- Department of Hematology, Hebei General Hospital, Shijiazhuang, China.
- Department of Rehabilitation, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Key Laboratory of Research and Development on Clinical Molecular Diagnosis for High-Incidence Diseases of Baise, Baise, Guangxi, China.
- Department of Hematology, Liaocheng People's Hospital, Liaocheng, China.
- Cardiology Department, The Third Xiangya Hospital of Central South University, Changsha, China.
ORCID-Profile: Huiling Qin, Dongcai Feng, Changyu Tian
Zitieren
APA
Zhang, Y., Xu, A., Qin, H., Feng, D., Tian, C., & Lin, C. (2026). miR ‐330‐3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4. APMIS, 134(7). https://doi.org/10.1111/apm.70237
Vancouver
Zhang Y, Xu A, Qin H, Feng D, Tian C, Lin C. miR ‐330‐3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4. APMIS. 2026;134(7). doi:10.1111/apm.70237
BibTeX
@article{Zhang2026,
author = {Zhang, Yuanyuan and Xu, Anni and Qin, Huiling and Feng, Dongcai and Tian, Changyu and Lin, Caiqin},
title = {miR ‐330‐3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4},
journal = {APMIS},
year = {2026},
volume = {134},
number = {7},
doi = {10.1111/apm.70237}
}
EUVIMED